Forbes-Tate
Forbes-Tate filed a Q2 report for Independent Pharmacy Cooperative on July 20, 2026, reporting $40,000 in lobbying income.
Lobbying for Independent Pharmacy Cooperative · Largest group purchasing organization for independent pharmacies.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act; Issues related to H.R. 3164 - Main Street Pharmacy Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation program; Issues related to S. 891 - Bipartisan Health Care Act; Issues related to S. 927 - Protecting Pharmacies in Medicaid Act; Issues related to H.R. 4317 - PBM Reform Act of 2025; Issues related to S. 2426 - Equitable Community Access to Pharmacist Services Act.
Issues related to Pharmacy Benefit Manager (PBM) transparency and reform and continued implementation of the Medicare Drug Price Negotiation Program in the One Big Beautiful Bill Act (P.L. 119-21).
Issues related to S.3822 - Break Up Big Medicine Act.